Compare DexCom, Inc. (DXCM) vs Goodyear Tire & Rubber Co (GT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Goodyear Tire & Rubber Co — how do they compare? DexCom, Inc. trades at $83.9 (market cap $31.86B), while Goodyear Tire & Rubber Co trades at $4.67 (market cap $1.37B). The key difference: DexCom, Inc. is far larger — about 23.3× Goodyear Tire & Rubber Co's market cap, and DexCom, Inc. is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Goodyear Tire & Rubber Co for 57 Days on average.
| DXCM | GT | |
|---|---|---|
Market Cap | $31.86B | $1.37B |
Volume | 3,607,070 | 9,470,773 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $10.54 |
52-Week Low | $54.84 | $4.66 |
Typical Hold Time | 62 Days | 57 Days |
Enterprise Value | $31.32B | $8.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Goodyear (GT) trades at $4.68, down 0.21% on the day, with a bearish technical signal and weak profitability metrics including a negative net income margin and ROE. Recent earnings show mixed results, with a Q2 2026 loss of $0.61 per share beating expectations but revenue declining. The company's restructuring efforts focus on premium tire segments and cost management, while cash flow trends show modest improvement with a net cash flow of $46 million in 2025.
The outlook remains challenging due to persistent losses and high debt, but analyst consensus suggests upside with a $8.00 price target. Key risks include volume pressure, competitive threats, and execution of the turnaround plan. Investment opportunity hinges on successful margin expansion and debt reduction, though near-term volatility is likely amid macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →
